Franklin Resources Inc Glycomimetics Inc Transaction History

Franklin Resources Inc

$346 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$1.13 - $2.54 $160 - $360	-142 Reduced 0.15%	95,751 $225,000
Q3 2023 Nov 13, 2023	SELL	$1.29 - $1.73 $31,963 - $42,865	-24,778 Reduced 20.53%	95,893 $143,000
Q3 2022 Nov 14, 2022	BUY	$0.55 - $0.9 $738 - $1,207	1,342 Added 1.12%	120,671 $67,000
Q2 2022 Aug 11, 2022	SELL	$0.54 - $1.15 $22,664 - $48,266	-41,971 Reduced 26.02%	119,329 $71,000
Q1 2022 May 13, 2022	BUY	$1.0 - $1.58 $993 - $1,568	993 Added 0.62%	161,300 $184,000
Q4 2021 Feb 11, 2022	SELL	$1.44 - $2.14 $565 - $841	-393 Reduced 0.24%	160,307 $231,000
Q3 2021 Nov 12, 2021	BUY	$1.8 - $2.39 $289,260 - $384,073	160,700 New	160,700 $352,000
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $4.81 Million - $22.1 Million	-1,718,779 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$10.6 - $13.12 $444,140 - $549,728	-41,900 Reduced 2.38%	1,718,779 $20.5 Million
Q1 2019 May 14, 2019	SELL	$9.96 - $13.44 $2.07 Million - $2.79 Million	-207,346 Reduced 10.54%	1,760,679 $21.9 Million
Q4 2018 Feb 12, 2019	SELL	$8.47 - $14.71 $409,101 - $710,493	-48,300 Reduced 2.4%	1,968,025 $18.6 Million
Q3 2018 Nov 13, 2018	SELL	$13.7 - $17.12 $2.02 Million - $2.53 Million	-147,500 Reduced 6.82%	2,016,325 $29 Million
Q2 2018 Aug 14, 2018	BUY	$14.63 - $19.19 $814,100 - $1.07 Million	55,646 Added 2.64%	2,163,825 $34.9 Million
Q1 2018 May 10, 2018	BUY	$16.06 - $25.35 $2.87 Million - $4.53 Million	178,800 Added 9.27%	2,108,179 $34.2 Million
Q4 2017 Feb 14, 2018	BUY	$10.51 - $17.22 $738,853 - $1.21 Million	70,300 Added 3.78%	1,929,379 $32.4 Million
Q3 2017 Nov 13, 2017	BUY	$10.14 - $14.85 $18.9 Million - $27.6 Million	1,859,079	1,859,079 $26 Million

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Account